anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Severe hemophilia is a rare, inherited, X-linked disorder. Currently, standard therapy involves ev infusion of drugs from a very young age.The diagnosis of hemophilia is a traumatic event for the parents, even before the unborn child. The management of the hemophilia patient involves the whole family. Also in relation to its heredity.Focus on the ways in which parents of children with hemophilia manage their emotional experience.he diagnosis of hemophilia brings with it, in parents, fears, guilt, overprotective temptations that push us to act rather than to narrate the meaning of that need of ours, caregiving modes that risk engaging our operational side at the expense of recognizing ourselves and our feelings and emotions. We have no reason to think that that traumatic stimulus installs in us an atypical mode of resorting to our emotional intelligence. Therefore, it becomes even more significant to study parent-child communication processes on this target, to observe whether and how the adult's emotional area finds its place and expression. On the results of this work, the foundations could be laid for subsequent observational or interventional studies.
Growing up is hard enough, and adolescence can be a particularly stressful time in people's lives as they adjust to the transition from childhood to adulthood. Peer pressure can add to this anxiety, making it more likely for teens to take part in risky behaviors such as smoking cigarettes. Every day, more than 4,000 teens smoke their first cigarette and nearly half of those teens will become regular, daily smokers. Cigarette smoking is associated with a multitude of health risks, including an increased likelihood of experiencing panic attacks, anxiety disorders, and depression. This study will evaluate a group of teens, ranging from those who have never smoked to those who smoke daily, to determine whether there is a relation between adolescent smoking history and their vulnerability to panic-producing situations.

Participants in this study will undergo a brief medical screening, followed by a short interview that will include several questionnaires regarding emotions, experiences, and personal habits. Participants will then attend a series of laboratory assessments for 1 hour. The first assessment will include a 3-minute voluntary hyperventilation procedure in which participants will be directed when to breathe in and when to breathe out, at a faster rate than normal. Participants will then take part in two computerized tasks: one will be a computerized task that involves blowing up a balloon and deciding when to quit before the balloon pops; the other task will involve choosing hypothetical amounts of money now or after a period of delay. During the laboratory assessments, all participants will have electrodes attached to their bodies and sensors around their chests to measure heart rate, palm sweating, and muscle tension. Results from this study will be used to evaluate the association between smoking and increased panic levels under stressful conditions among adolescents.
Major depression affects 5%-9% of older primary care patients, is often chronic or recurrent and disabling, and leads to frequent use of medical services. Most depressed elders are treated by primary care physicians (PCPs) and prior research has shown that collaboration between primary care physicians and depression care managers is effective in treating depression. The challenge has been in securing third-party reimbursement for such services.

This research study will address this barrier by developing a collaborative depression care management model (C-DCM) that encourages collaboration between PCPs and trained social workers employed by community-based, public and nonprofit mental health clinics. In addition to developing C-DCM, a total of 112 primary care outpatients will participate in this study to test whether C-DCM is more effective than the standard of care in decreasing the severity of depression and disability experienced by older adults. Each subject will be randomized into either Usual Care or C-DCM. All subjects will be assessed at Baseline and at 2 and 4 months while the C-DCM subjects will also meet with social worker depression case managers bi-weekly over four months. If shown effective, C-DCM may bring to bear an available, yet untapped resource in the care of depressed elders.
The present invention relates to Chinese medicine preparation for treating hepatic disease, particularly to a hundred herbal medicine preparation for treating hepatic disease. The hepatic disease refers that different reasons cause diffuse inflammation or wide substantive variation of the human body's liver, hepatic disease is caused boy many reasons, alcoholism is the main reason, and the harm of hepatitis b to a human body is most serious. Because the disease source is various, the expression in an organism is different, and the existing medicine can not perform satisfied effects. The present invention is prepared from 30 to 60 parts of bupleurum root, 20 to 40 parts of bull horn, 30 to 80 parts of cactus, 10 to 30 parts of bear gall, 10 to 30 parts of antelope horn, 20 to 50 parts of curcuma root, 30 to 50 parts of tuckahoe, 50 to 100 parts of plantain seed, 40 to 60 parts of akebia stem, 30 to 60 parts of coptis, 100 to 200 parts of golden buckwheat rhizome, etc. The present invention used for treating advanced hepatic disease, such as virus hepatitis, hepatitis b, hepatic ascites, hepatic cirrhosis, hepatic carcinoma, etc. has the advantages of no recurrence and high cure speed.
UNLABELLED: Hypophosphatasia (HPP) is a rare bone disease with limited scientific evidence on the tolerability and safety of its novel treatment, Asfotase Alfa (AA). We report 7 HPP patients' heterogenous presentations and the significant improvement in various clinical outcomes attained with AA shedding light on this highly effective and safe therapy.
INTRODUCTION: Hypophosphatasia (HPP) is a rare inherited metabolic bone disorder characterized by a deficiency in the tissue non-specific alkaline phosphatase (TNSALP) due to loss of function mutation in the ALPL gene. HPP is associated with impaired skeletal mineralization due to elevations in inorganic pyrophosphate and altered phosphate : pyrophosphate ratio. Asfotase alfa (AA) "enzyme replacement" was approved for treatment of HPP in 2015. We present 7 patients with HPP, 5 with pediatric-onset, and 2 with adult-onset, who have been treated with AA and describe the efficacy and safety in these patients.
METHODS: 7 patients (4 females, 3 males) aged 19-68 years with HPP were included in this study. Diagnosis of HPP was confirmed by DNA analysis. AA was administered in doses of 6mg/kg/week with a mean follow-up of 6 months (SD= 5).
RESULTS: Subjective improvement in muscle strength, muscle pain, walking ability, and walking distance with a reduction in the use of gait aids was seen "with AA in HPP patients." Muscle strength and pain improved by up to 70% from baseline as quantified subjectively by patients. Walking distance improved by up to 100%. Patients also reported improved cognition, mood, and energy levels, with up to 90% improvement in mood and 75% improvement in energy levels. 4 out of 6 patients first noted clinical signs of improvement after 3 months of being on therapy. 1 out of the 7 patients sustained a toe fracture 10 months from being on AA. AA was well-tolerated with injection site reactions being the most reported adverse effect.
CONCLUSION: HPP treatment with AA in individuals with both pediatric and adult-onset forms resulted in significant subjective improvement in musculoskeletal and cognitive manifestations in addition to patients' quality of life. The drug was well tolerated in 6 patients. 1 patient discontinued therapy because of minor adverse effects with myalgias.
Detrusor underactivity, a condition in which the bladder muscle does not contract strongly or long enough to empty the bladder completely or within the normal time frame, is a common cause of lower urinary tract symptoms in older individuals of both sexes. Although aging is a known risk factor for detrusor underactivity, its pathophysiological mechanisms are not fully understood. Therefore, establishing animal models that closely mimic the pathophysiology of detrusor underactivity in humans is necessary to elucidate these mechanisms. Metabolic syndrome is a cluster of several risk factors, including obesity, hyperlipidemia, hyperglycemia, and hypertension, which are associated with the development of diabetes, cardiovascular disease, and lower urinary tract dysfunction in both sexes. Notably, bladder dysfunction resulting from detrusor underactivity is observed at an earlier age in animal models with diabetes mellitus than in those without. Recently, detrusor underactivity-like phenotypes have been observed at a relatively early age in animal models with metabolic syndrome, involving obesity, hyperlipidemia, and hypertension, compared with those without. Therefore, this review introduces the association of detrusor underactivity with aging and metabolic syndrome, as well as possible pathophysiological mechanisms for detrusor underactivity from reports of various animal models. Notably, metabolic syndrome may accelerate the onset of age-related detrusor underactivity, and further analysis of old animal models with metabolic syndrome may help elucidate the pathogenesis of detrusor underactivity in humans.
Myositis, an autoimmune muscle disease, likely develops as a result of environmental exposures in genetically susceptible persons. Preliminary data suggest a trend for an increasing incidence in myositis in military personnel over the last decade for unknown reasons. Although a few environmental exposures have been preliminarily associated with myositis in the civilian population, these have not been confirmed. In addition, no study has assessed exposures that might result in the development of myositis in military personnel. Military personnel experience a number of intense, unique exposures, often over a relatively short interval, which include different stresses, novel vaccines, distinct occupational exposures, battlefield injuries and unique chemicals during field deployment, that differ from those exposures in non-military populations. Therefore, we propose a protocol that consists of three complementary approaches to attempt to determine the environmental factors associated with the development of myositis in active duty military personnel and an initial understanding of the possible mechanisms involved. In the first approach, we will assess risk factors in a case-control study of 300 patients who developed myositis while on active duty by comparing them to 1500 active duty military personnel (randomly selected, but matched 5:1 by gender, race, and age and military service within 10 years) who have not been diagnosed with an autoimmune disease or chronic muscle disease. For this first approach, we will analyze existing military databases for information on medications, vaccines, infections, co-existing medical conditions, military occupations, deployments, and worldwide active duty locations. In the second case-control approach, we will attempt to define environmental factors associated with the development of myositis that developed in military personnel (n=150) by comparing them to 150 similarly matched military personnel who have not been diagnosed with an autoimmune disease or chronic muscle disease. This second approach will differ from the first approach, in that subjects will be prospectively enrolled and assessed during a single clinic visit to confirm diagnoses and examine patient questionnaires on focused environmental exposures, including those not captured in the military databases. A third laboratory approach will identify, in an exploratory study, the global DNA methylation epigenetic changes, microRNA and mRNA profiles in peripheral blood and muscle tissues from 18 subjects (six PM and six DM compared to six non-myositis controls enrolled in the second approach) and assess the effects of selected environmental exposures on these parameters. These complementary approaches should enhance the understanding of environmental factors and possible mechanisms associated with the development of myositis in the military, and provide insights into environmental risk factors that may also be relevant to the development of myositis in non-military populations.
The invention relates to a derivative of a GLP-1 analogue of a general Formula I, which derivative comprises a side chain attached to a Lys residue at position 34, 35, 36, 37, 38, or 39 of the GLP-1 analogue. The side chain comprises a Branched linker, a 1 st  and a 2 nd  Protractor and a Pre-linker. The Branched linker is connected to the Lys residue of the GLP-1 analogue via the Pre-linker and to the 1 st  and the 2 nd  Protractor via a 1 st  and 2 nd  Post-linker, respectively. The Branched linker may, e.g., be a tri-radical of Lys. The 1 st  and the 2 nd  Protractor is C20 diacid. Various linker elements may be used in the Prelinker as well as the two Post-linkers. The invention also relates to novel GLP-analogues, novel side chain intermediates and their manufacture and use to prepare derivatives of biologically active peptides and proteins, as well as pharmaceutical compositions and medical uses of the analogues and derivatives. The derivatives have very long half-lives while maintaining a satisfactory potency, which makes them potentially suitable for once-monthly administration.
INTRODUCTION: Sugammadex, a novel selective antagonist of non-depolarizing neuromuscular blocking agents, has been shown to rapidly and effectively reverse moderate and deep paralysis in adults and pediatric patients over age 2, improving patient recovery and reducing the risk of postoperative complications.
AREAS COVERED: Since the use of sugammadex in patients under age 2 is not widely studied, we aim to provide an overview on the drug's application and potential use in infants and neonates. There is a limited but growing body of evidence for the safe, efficacious use of sugammadex in children under age 2. Relevant studies were identified from the most updated data including case reports, clinical trials, systematic reviews, and meta analyses.
EXPERT OPINION: The results suggest that at a dose of 2 to 4 mg/kg of sugammadex can be safely used to rapidly and effectively reverse neuromuscular blockade in neonates and infants; it is non-inferior based on incidence of adverse events compared to neostigmine. Additionally, sugammadex doses between 8 and 16 mg/kg may be used as a rescue agent for infants during 'can't intubate, can't ventilate' crisis. Overall, sugammadex offers new value in the perioperative care of patients under age 2, with further studies warranted to better understand its application and full effect in the pediatric population.
Adult participants (\>18 yr) who plan to receive annual physical examination and low-dose computed tomography will be included. And those who have history cancers, received anti-tumor treatment before surgery, liver disease, or infections will be excluded.
APOKYN treatment before the PT Intervention Visit. Subjects in the "APO+" group will administer their usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
Given the increasing awareness of the negative effects of fatigue on daily activities, mental health, and quality of life, antifatigue supplements are becoming increasingly popular among consumers. Selenium has been found to have antifatigue potential in high dosage, but may cause toxicity effects to the body. In this study, inorganic selenium was first converted to nanoselenium particles via in situ synthesis by Lactobacillus rhamnosus SHA113 (Se-LRS), and then loaded by Ganoderma lucidum spores (GLS). The resulting products were not only assessed for their antioxidant activities, but also the antifatigue potential in mice. As a result, both Se-LRS and the Se-LRS/GLS complex exhibited higher antioxidant and antibacterial activities in simulated gastrointestinal fluids compared to isolated selenium nanoparticles. The Se-LRS/GLS complex demonstrated sustained release of selenium in simulated gastrointestinal fluids and showed significant alleviation of exercise-induced fatigue indicators, but relatively lower liver selenium accumulation in the mice, surpassing the effects of isolated nanoselenium. No toxicity was found to Caco-2 cells for Se-LRS/GLS complex at 2 µg/mL. This is a novel approach to enhance the antifatigue potential of selenium without causing extra toxicity.
This condition will reflect training as usual. Training will involve the same content contained in the asynchronous self-directed digital training platform, except delivered over a one day (4.5 hours of online instruction) workshop; and residents will be required to do the same reading and homework of lesson plans and viewing of the on-line videotaped role plays (an additional \~7.5 hours in total).
This cohort includes patients with newly diagnosed IDH wild-type glioblastoma, grade 4, according to the 2021 WHO classification of Central Nervous System Tumors. Patients in this group will undergo personalized radiotherapy guided by artificial intelligence (AI) and multiparametric MRI, using predictive models to adjust treatment volumes and doses according to areas of tumor infiltration. The AI model, developed from radiomic characteristics of postoperative MRI, predicts tumor recurrence and infiltration, enabling targeted dose escalation to high-risk areas while minimizing radiation exposure to healthy tissues.
When tamoxifen is used in combination with coumarin-type anticoagulants, a significant increase in anticoagulant effect may occur. Where such coadministration exists, careful monitoring of the patient's prothrombin time is recommended.

In the NSABP P-1 trial, women who required coumarin-type anticoagulants for any reason were ineligible for participation in the trial (see CONTRAINDICATIONS).

There is an increased risk of thromboembolic events occurring when cytotoxic agents are used in combination with tamoxifen.

Tamoxifen reduced letrozole plasma concentrations by 37%. The effect of tamoxifen on metabolism and excretion of other antineoplastic drugs, such as cyclophosphamide and other drugs that require mixed function oxidases for activation, is not known. Tamoxifen and N-desmethyl tamoxifen plasma concentrations have been shown to be reduced when coadministered with rifampin or aminoglutethimide. Induction of CYP3A4-mediated metabolism is considered to be the mechanism by which these reductions occur; other CYP3A4 inducing agents have not been studied to confirm this effect.

One patient receiving tamoxifen with concomitant phenobarbital exhibited a steady-state serum level of tamoxifen lower than that observed for other patients (i.e., 26 ng/mL vs. mean value of 122 ng/mL). However, the clinical significance of this finding is not known. Rifampin induced the metabolism of tamoxifen and significantly reduced the plasma concentrations of tamoxifen in 10 patients. Aminoglutethimide reduces tamoxifen and N-desmethyl tamoxifen plasma concentrations. Medroxyprogesterone reduces plasma concentrations of N-desmethyl, but not tamoxifen.

Concomitant bromocriptine therapy has been shown to elevate serum tamoxifen and N-desmethyl tamoxifen.

Based on clinical and pharmacokinetic results from the anastrozole adjuvant trial, tamoxifen should not be administered with anastrozole (see CLINICAL PHARMACOLOGY, Drug-Drug Interactions).
PURPOSE:To improve practicable curing time and strength and excellent bioaffinity by incorporating alpha-tricalcium phosphate and tetracalcium phosphate as essential components into the above filling material and further incorporating at least >=1 kinds of the hydroxide or oxide of alkali metals or alkaline earth metals therein. CONSTITUTION:The weight ratio of the alpha-tricalcium phosphate and tetracalcium phosphate is preferably 9:1 to 1:9, more particularly preferably 8:2 to 1:9. The hydroxide or oxide of alkali metals or alkaline earth metals is the compd. which can adjust the pH of the cured matter of the filling material for the osteodefective, osteospace and root canal parts to the neighborhood of neutrality of about 7 pH; for example, the oxide is exemplified preferably by caustic soda, caustic alkali, magnesium hydroxide, calcium hydroxide, etc., and the oxide is preferably exemplified by Na2O, K2O, MgO, CaO, etc. The content ratio to the hydroxide or oxide into the filling material is preferably 0.5 to 20wt.%, and is more particularly preferably changed property according to the compsn. ratio of the alpha-tricalcium phosphate and tetracalcium phosphate.
PURPOSE: The purpose of this study is to identify if the local institutional shift from routine overnight observation to same-day discharge following percutaneous cryoablation (PCA) of renal tumors increases 30 day re-admission rates or serious adverse events (AEs).
MATERIALS AND METHODS: This retrospective study included 133 adult patients. PCA patients in calendar years 2018-2019 were routinely observed overnight in the hospital, comprising the control group (Group A). PCA patients in calendar years 2021-2022 were routinely discharged the same day, comprising the test group (Group B). Relevant demographic information, tumor characteristics, technical outcomes, and clinical outcomes were recorded.
RESULTS: 15 patients (11.3 %) from the total cohort were re-admitted to the hospital within 30 days of PCA for any reason. Seven patients (10.4 %) and eight patients (12.1 %) were re-admitted for any reason within 30 days in Group A and Group B, respectively, with no difference between the two groups (p = 0.76). Nine patients (6.8 %) from the total cohort were re-admitted to the hospital within 30 days for a diagnosis secondary to the procedure. Four patients (6 %) and five patients (7.6 %) were re-admitted within 30 days for reasons related to PCA in Group A and Group B, respectively, with no significant difference between the groups (p = 0.71). Eight patients (12 %) and four patients (6 %) had major AEs following PCA in Group A and Group B, respectively, with no difference between the two groups (p = 0.43).
CONCLUSION: Overall, the change in post-procedural care after PCA did not have a deleterious effect on 30 day re-admission rates or rates of major AEs.
PROBLEM TO BE SOLVED: To prepare the subject composition, capable of imparting homogeneous permanent waves to hair without damaging hair even by repetitive application by making the composition contain a pearl protein hydrolyzate therein. SOLUTION: This permanent waving agent composition contains a pearl protein hydrolyzate in an amount of 0.05-5wt.% based on the total composition in a base containing at least one reducing organic thio compound and/or at least one inorganic sulfite. A commercially available pearl protein hydrolyzate can be used as the pearl protein hydrolyzate. An alkalifying agent, a surfactant, etc., can further suitably be compounded. The resultant composition has excellent waving effects and good conditioning effects and is capable of providing elastic curls and good combing properties and good gloss to hair. The composition, as necessary, can be used as a hair pretreating agent or an intermediate treatment agent.